PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555547
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555547
Phenobarbital Market size was valued at USD 1,590.32 million in 2023, expanding at a CAGR of 5.10% from 2024 to 2032.
Phenobarbital, a member of the barbiturate drug class, has a wide range of therapeutic uses. It is effective in managing seizures and treating status epilepticus, and insomnia. Additionally, it plays a crucial role in addressing benzodiazepine and alcohol withdrawal symptoms. Phenobarbital is utilized for seizure control, anxiety relief, and prevention of withdrawal symptoms in individuals dependent on other barbiturate medications. Belonging to the class of barbiturates, Phenobarbital functions by slowing down brain activity.
Phenobarbital Market- Market Dynamics
The increasing prevalence of epilepsy is expected to propel market demand
The growing incidence of epilepsy across the globe significantly contributes to the rising demand for antiepileptic drugs, such as phenobarbital. Epilepsy, a prevalent neurological condition marked by recurrent seizures, is experiencing an increase in cases, thereby intensifying the need for effective treatment alternatives. According to the World Health Organization, approximately 50 million individuals worldwide are affected by epilepsy, making it one of the most widespread neurological disorders. Notably, nearly 80% of those with epilepsy reside in low- and middle-income countries. Additionally, the enhancement of healthcare infrastructure and increased awareness in developing regions may present new opportunities for market expansion. However, limited awareness in certain areas could hinder market growth.
Phenobarbital Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.10% over the forecast period (2024-2032)
Based on Type segmentation, Epilepsy was predicted to show maximum market share in the year 2023
Based on Dosage Form segmentation, Tablets was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Phenobarbital Market is segmented based on Type, Dosage Form, Application, and Region.
The market is categorized into two segments based on Type: Epilepsy and Neonatal Seizures, with the Epilepsy segment leading in market share. Phenobarbital is frequently utilized in the management of pediatric epilepsy, including cases involving newborns experiencing seizures, owing to its proven efficacy and safety when administered judiciously.
The market is segmented into three categories according to Dosage Form: Tablets, Capsules, and Injectable. Tablets are the leading category in the market. Phenobarbital tablets have a strong foothold in the pharmaceutical market, particularly in the management of epilepsy.
The market is segmented into three categories according to Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Every channel has a crucial part in guaranteeing that patients obtain this necessary medication in a way that accommodates their requirements and situations.
Phenobarbital Market- Geographical Insights
Geographically, this market spans across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented based on the countries involved in business activities. North America leads the market, primarily due to the rising number of traumatic brain injuries caused by accidents. Particularly in the United States and Canada, North America witnesses high occurrences of traumatic brain injuries resulting from road accidents, sports, falls, and other incidents. These injuries often lead to seizures, thereby increasing the demand for effective antiepileptic treatments such as phenobarbital. The Centers for Disease Control and Prevention projected that there will be more than 69,000 TBI-related deaths in the United States in 2021, equating to approximately 190 TBI-related deaths per day. Europe holds the second-largest market region for growth, attributed to advancements in formulations.
The competitive landscape of the phenobarbital market is shaped by a variety of factors, such as the rivalry among pharmaceutical companies, the existence of generic options, and market trends. Leading pharmaceutical companies with a rich history in the market are key players in the production of phenobarbital. These companies may vie for market share by introducing innovative formulations or delivery systems like extended-release tablets or combination treatments. Competition will continue to play a crucial role in determining the availability, pricing, and overall dynamics of the market as it progresses.
Pfizer Inc. made an announcement nowadays regarding the approval of PAXLOVID (nirmatrelvir tablets and ritonavir tablets) by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19, such as hospitalization or death.
On February 5, 2024, Novartis disclosed its decision to engage in a voluntary public takeover bid to acquire MorphoSys AG, a biopharmaceutical company headquartered in Germany that specializes in the development of groundbreaking oncology treatments.